High Growth Tech Stocks In South Korea To Watch

The South Korean stock market has shown resilience, ticking higher after a brief pause in its upward trajectory, with the KOSPI index nearing the 2,600-point mark amid mixed performances across various sectors. As global sentiment softens due to interest rate concerns and economic indicators remain under close watch, investors are increasingly focused on identifying high-growth opportunities within the tech sector that can thrive despite broader market fluctuations.

Top 10 High Growth Tech Companies In South Korea

Name	Revenue Growth	Earnings Growth	Growth Rating
IMLtd	21.80%	111.43%	★★★★★★
Seojin SystemLtd	33.39%	49.13%	★★★★★★
Bioneer	23.53%	97.58%	★★★★★★
NEXON Games	29.64%	66.98%	★★★★★★
FLITTO	32.60%	106.82%	★★★★★★
ALTEOGEN	64.22%	99.46%	★★★★★★
Devsisters	29.08%	63.02%	★★★★★★
Park Systems	23.21%	34.63%	★★★★★★
AmosenseLtd	24.04%	71.97%	★★★★★★
UTI	114.97%	134.60%	★★★★★★

Click here to see the full list of 48 stocks from our KRX High Growth Tech and AI Stocks screener.

Underneath we present a selection of stocks filtered out by our screen.

ALTEOGEN (KOSDAQ:A196170)

Simply Wall St Growth Rating: ★★★★★★

Overview: ALTEOGEN Inc. is a biotechnology company specializing in the development of long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars, with a market cap of ₩19.60 trillion.

Operations: The company generates revenue primarily from its biotechnology segment, amounting to ₩90.79 billion. It focuses on developing innovative biopharmaceutical products, including long-acting biobetters and antibody-drug conjugates.

ALTEOGEN is navigating the dynamic biotech landscape with a strategic focus on R&D, which is evident from its substantial investment in this area. With an impressive forecasted revenue growth rate of 64.2% per year, the company outpaces the broader South Korean market's average of 10.5%. Despite current unprofitability, earnings are expected to surge by 99.5% annually, positioning ALTEOGEN for a robust turnaround. This growth trajectory is supported by an anticipated high Return on Equity of 66.3% in three years, underscoring potential future financial health and operational efficiency. The company's commitment to innovation and development in biotechnologies could significantly influence its sector's evolution, making it a noteworthy entity in South Korea's high-tech ecosystem despite some present challenges.

• Unlock comprehensive insights into our analysis of ALTEOGEN stock in this health report.

• Understand ALTEOGEN's track record by examining our Past report.

Lunit (KOSDAQ:A328130)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Lunit Inc. specializes in developing AI-based software solutions for cancer screening, diagnosis, and treatment with a market capitalization of ₩1.18 billion.

Operations: The company generates revenue primarily from its healthcare software segment, amounting to ₩26.03 billion.

Lunit, a South Korean tech firm, is making significant strides in healthcare AI with its Lunit INSIGHT CXR software, which recently showcased a top performance in TB detection. This achievement is underscored by an independent study published in The Lancet Digital Health, marking a critical advancement in combating underdiagnosis of TB globally. Financially, Lunit's revenue growth forecast at 51.8% annually outpaces the local market average significantly. Coupled with an expected surge in earnings by 104.9% per year, these figures highlight the company’s potential amidst a volatile share price and current unprofitability. R&D investments remain pivotal to sustaining this momentum, ensuring Lunit remains at the forefront of technological innovation within the high-demand AI health sector.

• Dive into the specifics of Lunit here with our thorough health report.

• Gain insights into Lunit's past trends and performance with our Past report.

Celltrion (KOSE:A068270)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Celltrion, Inc., along with its subsidiaries, specializes in the development and production of protein-based drugs for oncology treatment in South Korea, with a market cap of ₩40.10 trillion.

Operations: Celltrion, Inc. focuses on producing protein-based oncology drugs, generating significant revenue from its Bio Medical Supply segment at ₩3.54 trillion. The company also earns from Chemical Drugs with a revenue of ₩507 billion.

Celltrion's strategic moves in the biotech sector underscore its commitment to expanding globally, evidenced by recent agreements enhancing ZYMFENTRA's accessibility in the U.S. market, targeting a substantial patient base. The company's R&D expenditure is robust, aligning with its innovative thrust; last year’s R&D spending ratio stood at 25.5% of revenue, supporting a pipeline that promises to fuel an earnings growth forecast of 59.6% annually. This focus on development is critical as it navigates through a challenging phase marked by a notable dip in net income from KRW 147.5 billion to KRW 78 billion year-over-year despite increased sales, reflecting investment back into its core areas and product expansion like SteQeyma® in Europe—a move set to capture more market share within specialty biologics for chronic diseases.

• Click here to discover the nuances of Celltrion with our detailed analytical health report.

• Assess Celltrion's past performance with our detailed historical performance reports.

Make It Happen

• Take a closer look at our KRX High Growth Tech and AI Stocks list of 48 companies by clicking here.
• Already own these companies? Link your portfolio to Simply Wall St and get alerts on any new warning signs to your stocks.
• Maximize your investment potential with Simply Wall St, the comprehensive app that offers global market insights for free.

Ready For A Different Approach?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com